Causes of death in HIV-1-Infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies

Clinical Infectious Diseases

Volumn 50, Issue 10, 2010, Pages 1387-1396

  May, Margaret ^a   Gill, John ^b,u   Lewden, Charlotte ^c   Saag, Mike ^d,p   Mugavero, Michael ^d   Reiss, Peter ^e,p   Ledergerber, Bruno ^f,z   Mocroft, Amanda ^g   Harris, Ross ^a   Fux, Christoph A ^h   Justice, Amy ^i,x   Costagliola, Dominique ^j,r   Casabona, Jordi ^k,q   Hogg, Robert S ^l,w   Khaykin, Pavel ^m   Lampe, Fiona ^n,z   Vehreschild, Janne ^o   Sterne, Jona Than A C ^a   Egger, Matthias ^t   Brodt, Hans Reinhard ^p   Chêne, Geneviève ^p   Dabis, François ^p   Monforte, Antonella D'Arminio ^s   De Wolf, Frank ^p   Fätkenheuer, Gerd ^p,r   Guest, Jodie ^v   Kirk, Ole ^y   Kitahata, Mari ^p   Sterling, Tim ^aa   more..

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j INSERM   (France)

^k CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^l SIMON FRASER UNIVERSITY   (Canada)

^m GOETHE UNIVERSITY   (Germany)

ⁿ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^o UNIVERSITY OF COLOGNE   (Germany)

^p PISCIS ^*

^q PISCIS   (Germany)

^r FHDH   (France)

^s ICONA   (France)

^t SHCS   (France)

^u South Alberta Clinic   (France)

^v HAVACS   (United States)

^w BCCfE HIV   (Canada)

^x VAC   (Canada)

^y EuroSIDA Coordinating Centre   (Denmark)

^z Sheila Sherlock Liver Center   (United Kingdom)

^aa VANDERBILT UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG ABUSE; DRUG FATALITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION; KIDNEY FAILURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; VIOLENCE; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 77951819361     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/652283     Document Type: Article

References (33)

1. ART-CC. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
2. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16:1663-1671. (Pubitemid 34921112)
3. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
4. Lau B, Sharrett AR, Kingsley LA, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006; 166:64-70. (Pubitemid 43063843)
5. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
6. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
7. World Health Organization. ICD-9, International Classification of Diseases and Related Health Problems, 9th revision. Geneva: World Health Organization, 1975.
8. World Health Organization. International Statistical Classification of Diseases and Related health Problems, 10th revision. Geneva: World Health Organization, 2007.
9. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129. (Pubitemid 34786200)
10. May M, Royston P, Egger M, Justice AC, Sterne JA. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med 2004; 23:2375-2398.
11. May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21:1185-1197. (Pubitemid 46763289)
12. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34:121-130. (Pubitemid 40347381)
13. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
14. Clifford GM, Rickenbach M, Polesel J, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008; 22:2135-2141.
15. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28:964-974. (Pubitemid 29525041)
16. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26:2389-2430. (Pubitemid 46730255)
17. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20:741-749. (Pubitemid 43884302)
18. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641. (Pubitemid 44232373)
19. Martinez E, Milinkovic A, Buira E, et al. Incidence and causes of death in HIV-infected, persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med 2007; 8:251-258. (Pubitemid 46695372)
20. Petoumenos K, Law MG. Risk factors and causes of death in the Australian HIV Observational Database. Sex Health 2006; 3:103-112. (Pubitemid 43829307)
21. Sabin CA, Smith CJ, Youle M, et al. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006; 20:67-71. (Pubitemid 41818116)
22. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34. (Pubitemid 44306484)
23. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis 2009; 48:633-639.
24. Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 20:561-565. (Pubitemid 43731600)
25. Post FA, Campbell LJ, Hamzah L, et al. Predictors of renal outcome in HIV-associated nephropathy. Clin Infect Dis 2008; 46:1282-1289.
26. Wyatt CM, Malvestutto C, Coca SG, Klotman PE, Parikh CR. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS 2008; 22:1799-1807.
27. Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197:1145-1155. (Pubitemid 351590050)
28. Nagot N, Ouedraogo A, Konate I, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis 2008; 198:241-249. (Pubitemid 352035760)
29. Daar ES, Lynn H, Donfield S, et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis 2001; 183:589-595. (Pubitemid 32147515)
30. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1 -infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447-454.
31. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360(18):1815-1826.
32. When To Start Consortium. Timing of initiation of antiretroviral therapy in. AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
33. Marin B, Thiebaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23:1743-1753.